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Summary
Impaired cardiovascular function has recently been
demonstrated to potentially reduce life expectancy
both in GH deficiency and excess. Experimental and
clinical studies have supported the evidence that GH
and IGF-I are implicated in cardiac development. In
most patients with acromegaly a specific cardiomyo-
pathy, characterized by myocardial hypertrophy with
interstitial fibrosis, lympho-mononuclear infiltration
and areas of monocyte necrosis, results in biventri-
cular concentric hypertrophy. In contrast, patients
with childhood or adulthood-onset GH deficiency
(GHD) may suffer both from structural cardiac
abnormalities, such as narrowing of cardiac walls,
and functional impairment, that combine to reduce
diastolic filling and impair left ventricular response to
peak exercise. In addition, GHD patients may have an
increase in vascular intima-media thickness and a
higher occurrence of atheromatous plaques, that can
further aggravate the haemodynamic conditions and
contribute to increased cardiovascular and cerebro-
vascular risk. However, several lines of evidence
have suggested that the cardiovascular abnormalities
can be partially reversed by suppressing GH and
IGF-I levels in acromegaly or after GH replacement
therapy in GHD patients.
Recently, much attention has been focussed on the
ability of GH to increase cardiac mass suggesting
its possible use in the treatment of chronic non-
endocrine heart failure. In fact, GH administration can
induce an improvement in haemodynamic and clini-
cal status in some patients. Although these data need
to be confirmed in more extensive studies, such
promising results seem to open new perspectives for
GH treatment in humans.
Introduction
GH and insulin-like growth factor I (IGF-I) are multifunctional
growth factors primarily known as regulators of longitudinal
bone growth. GH works as an endocrine promoter of hepatic
production of IGF-I, which ultimately mediates GH action on
peripheral tissues. These hormones elicit primary regulatory
activities both in the developmental growth of the heart and in
the maintenance of its structure, but autocrine and paracrine
mechanisms exerted by IGF and their binding peptides might
also be involved (Isgaard et al., 1989; Toyozaki et al., 1993;
Delafontaine, 1995). After cessation of body growth, GH still
has a physiological role in the human body. It is evident that
GH plays a positive effect on body composition, muscle
strength, bone mineral density, reproductive capacity, skin
properties and metabolic functions (De Boer et al., 1995).
Interestingly, the existence of a relationship between GH/IGF-I
and the cardiovascular system has long been suggested
(Huchard, 1895), and an increased risk for cardiovascular
morbidity and mortality has been documented both in GH
excess and deficiency (Wright et al., 1970; Nabarro, 1987;
Rose´n & Bengtsson, 1990; Bates et al., 1993, 1996;
Rajasoorya et al., 1994; Sacca` et al., 1994; Bulo¨w et al.,
1997; Bengtsson et al., 1998; Orme et al., 1998). Changes of
plasma volume also occur both in GH excess and deficiency.
In fact, GH causes fluid retention in patients with acromegaly
(Ikkos et al., 1954) while patients with GH deficiency have
decreased extracellular volume and plasma volume which is
restored by GH replacement (Møller et al., 1997). The
alteration of body fluids play a concomitant role in the
impairment of the cardiac performance in these patients.
The aim of this study is to review some of the most recent
experimental and clinical evidence concerning the interaction
of GH and IGF-I with cardiovascular function. Cardiac
consequences of GH excess and deficiency in humans and
their possible reversibility after medical treatment are also
discussed together with the potential indication for GH
treatment in patients with heart failure.
Effect of GH on the heart: the experimental basis
Cardiomyocytes are almost unequivocally considered as
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terminally differentiated cells unable to proliferate. They
respond to biomechanical stress, like pressure and volume
overload, by remodelling and hypertrophy, and re-expressing
fetal cytoskeletal and myofibrillar proteins (Reiss et al., 1994).
From a physiological point of view, several components of the
IGF family can be expressed in an autocrine/paracrine fashion
within the heart. Both the epicardium and the coronary vessel
of the human fetus express IGF-I mRNA (Han et al., 1987). In
the neonatal rat, the ventricles preferentially express IGF-II
mRNA transcripts and contain both IGF-I receptor type 1 and 2
(Engelmann et al., 1989). In the adult rat, cardiac IGF-I
transcription and IGF-I receptor expression is partly blunted
(Anversa et al., 1986; Toyozaki et al., 1993; Delafontaine,
1995; Le Roith et al., 1995). In addition, increased IGF-I
immunoreactivity has been found in the inner layers of the left
ventricle (Wahlander et al., 1992) where both tension and wall
stress are high, with a gradual decline towards the epicardial
surface (Mirsky, 1979). No elevation of IGF-I expression has
been observed in the right ventricle (Isgaard et al., 1999).
Interestingly, the onset of IGF-I expression preceded or
paralleled the development of left ventricular hypertrophy
(Wahlander et al., 1992; Guron et al., 1996).
The involvement of the IGF system in rat experimental
cardiopathy suggests that co-ordinated gene expression is
activated (Delafontaine, 1995), and that IGF-I, IGF receptors
and IGF binding proteins (IGFBPs) can take part to the
response to increased workload (Guron et al., 1996),
inflammation-linked angiogenesis (Schaper et al., 1994; Kluge
et al., 1997) and repair processes following ischaemic events
(Dean et al., 1999). The expression of IGF-I mRNA and IGF
receptors is increased in both ventricles following pressure
and volume overload (Komuro & Yazaki, 1993; Donohue et al.,
1994), experimental infarction and cardiac hypertrophy
(Donohue et al., 1994). Post-ischaemic heart failure is
associated with a higher expression of IGFBP-3, 4, 5 and 6
in the infarct/peri-infarct area of the left ventricle (Kluge et al.,
1997; Dean et al., 1999). The activation of genes essential to
DNA synthesis is supposed to act in a pathological context as a
repair mechanism for the reconstitution of damaged cardiac
tissue (Reiss et al., 1994). Despite this evidence, it is still
difficult to understand the real importance of IGF-I in prenatal
life, as far as development of the heart is concerned. An
increase of IGF-I mRNA was found in rat myocardium after
pressure overload secondary to either banding of the ascending
aorta, aorto-caval shunting, myocardial infarction secondary to
experimental renal hypertension and induction of pulmonary
hypertension (Wahlander et al., 1992; Hanson et al., 1993;
Russel-Jones et al., 1993; Isgaard et al., 1994; Reiss et al.,
1994). In fact, newborns of knock-out mice for the IGF-I gene
show a reduced body size as compared to control litter-mates,
but the heart size is generally unaffected (Wang et al., 1999).
Similarly, when hepatic IGF-I synthesis is knocked-out with
the Cre/loxP recombination system, no negative effect on the
postnatal cardiac size can be detected (Sjogren et al., 1999).
Otherwise, several lines of evidence suggest that the rate
of GH secretion has a prominent role in postnatal cardiac
development. Rats subjected to pituitary excision show
decreased cardiac expression of IGF-I mRNA, which can be
restored by exogenous rGH administration (Flyvbjerg et al.,
1991). GH-secreting tumours implanted in rats induce cardiac
hypertrophy, enhance contractile performance and induce the
action potential of cardiac fibres (Courville & Mason, 1938;
Hunter & Chien, 1999). The exogenous administration of GH
and IGF-I in normal adult rats induced a cardiac hypertrophic
response without development of significant fibrosis (Cittadini
et al., 1996). Furthermore, IGF-I increases intracellular
calcium content and enhances the calcium sensitivity of
myofilaments in cardiomyocytes (Xu & Best, 1991; Freestone
et al., 1996; Cittadini et al., 1998). GH and IGF-I stimulation
of the cardiac fibre is associated with a low-energy conforma-
tional feature, through the myosin pheno-conversion from the
isoform V3 to a low ATPase activity isoform (Rubin et al.,
1990; Xu & Best, 1991). GH and IGF-I also play a direct effect
on myocardial contractility. Increased contractility was shown
in preparations of cardiac tissue from animal models of chronic
GH excess (Timsit et al., 1990), or in cardiomyocytes from
neonatal rats (Vetter et al., 1988), likely due to increased
calcium responsiveness of myofilaments (Stro¨mer et al., 1996).
However, it is hard to separate the effects elicited by
GH from those directly due to IGF-I. In humans, the acute
intravenous infusion or subcutaneous administration of re-
combinant IGF-I to healthy subjects has been reported to
increase cardiac performance, as assessed by impedance
cardiography or echocardiography (Russell-Jones et al.,
1995; Donath et al., 1996). Systemic side-effects with
metabolic changes were induced by the intravenous infusion
of 60 mg/kg of IGF-I over 3 h (Russell-Jones et al., 1995), but
not when the same dose was given subcutaneously (Donath
et al., 1996). In this study, glucose levels were unchanged
while insulin levels and the GH response to physical exercise
were inhibited (Donath et al., 1996). Moreover, subcutaneous
injection of 20 mg/kg of IGF-I was demonstrated to enhance
cardiac inotropism in healthy subjects (Bisi et al., 1999a). The
IGF-I-induced increase in the LV ejection fraction could be
due not only to a direct cardiac action but also to a secondary
vasodilatation. In fact, IGF-I displays vasodilator effects in
forearm muscles and kidneys (Guler et al., 1989; Hirschberg &
Kopple, 1989; Copeland & Sreekuran, 1994). An alternative
explanation might involve cathecolamine release, although
the results reported by Bisi et al. (1999a) did not show
changes in epinephrine or norepinephrine secretion after
rIGF-I administration.
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Cardiovascular effects of GH excess
In humans, chronic excess of GH and IGF-I secretion is able to
affect heart morphology and performance (Wright et al., 1970;
McGuffin et al., 1974). Cardiac involvement in the theoretical
absence of other cardiac disease can define acromegalic
cardiomyopathy, which most commonly features concentric
hypertrophy (McGuffin et al., 1974). Cardiac walls are
thickened, but cardiac chambers are rarely enlarged, an event
resulting from the relative increase in cardiac myocyte width,
due to the parallel assembly of new contractile-protein units
(Hunter & Chien, 1999). Biopsy and autopsy studies have
shown that interstitial fibrosis constitutes the main histological
abnormality and it gradually impairs the organ architecture
(Courville & Mason, 1938; Hejtmancik et al., 1951; Lie
& Grossman, 1980; Hayward et al., 1987). Extracellular
deposition of collagen is increased and coexists with
myofibrillar derangement, areas of monocyte necrosis and
lympho-mononuclear infiltration, thus resembling a pattern of
myocarditis (Hejtmancik et al., 1951; Lie & Grossman, 1980;
Hayward et al., 1987). In vivo examination of biopsy
specimens, obtained during heart catheterization, showed
increased apoptosis in cardiac myocytes and interstitial
fibroblasts, found to be inversely correlated to the output
rate (Frustaci et al., 1999).
From a clinical perspective, heart hypertrophy is the most
widely described feature of the cardiac involvement in
acromegaly (Wright et al., 1970; McGuffin et al., 1974;
Savage et al., 1979; Smallridge et al., 1979; Hayward et al.,
1987; Morvan et al., 1991; Fazio et al., 1993; Colao et al.
2000a). Although the hypertrophy of the left ventricle is
prominent, evidence has been provided that the right ventricle
can be equally involved (Fazio et al., 1993). Ageing and long
duration of acromegaly are main determinants of heart
derangement and results collected in vivo and postmortem
show a cardiac hypertrophy rate higher than 90% in patients
with a long disease duration (Hejtmancik et al., 1951; Lie &
Grossman, 1980). More recent surveys suggest that structural
changes of the heart can even occur in patients after short-term
exposure to GH hypersecretion (Colao et al., 1997a; Fazio et al.
2000), and at least 20% of normotensive patients aged under
30 years have been found to have cardiac hypertrophy (Minniti
et al., 1998). Functionally, in the early phase of acromegaly,
and thus in young patients with a short disease duration,
high heart rate and increased systolic output configure the
hyperkinetic syndrome (Thuesen et al., 1988). In a review of
our series, the left ventricular (LV) mass index (LVMi) was
found to be significantly increased in patients with active
acromegaly aged below 40 years and estimated disease
duration between 3 and 7 years, as compared to age-matched
controls, and 54·5% of them had clear-cut echocardiographic
signs of LV hypertrophy (defined as LVMi $ 110 g/m2 in
women and $ 135 g/m2 in men) (Fig. 1). In active acrome-
galic patients aged 41–60 years and with estimated disease
duration of 5–15 years, the LVMi was significantly higher
than in age-matched controls, and 72·2% of them had LV
hypertrophy (Fig. 1). This finding confirmed data obtained in
another cohort of patients (Colao et al., 1997a), suggesting
that cardiac hypertrophy can be an early sign of acromegaly,
which is worsened as long as GH/IGF-I hypersecretion is left
untreated.
Other factors can potentially contribute to the cardiac
derangement in acromegaly. Arterial hypertension affects at
least one-third of patients and it can accelerate the develop-
ment of cardiac hypertrophy (Lo´pez-Velasco et al., 1997). A
survey performed on a large number of acromegalic patients
studied at their diagnosis (Colao et al. 2000a), allowed us to
observe that hypertension and, additionally, glucose intoler-
ance can significantly increase the impact of cardiac
hypertrophy, that was documented in 51% of the cases
included in this series. The prevalence of hypertrophy was
found to be significantly higher both in hypertensive and
diabetic patients, and multivariate analysis showed that the
diastolic blood pressure could better predict the presence of
cardiac hypertrophy (Colao et al. 2000a). The concomitant
development of thyrotoxicosis, which has been reported to
represent a rare complication of acromegaly, can also induce a
significant impairment of both cardiac mass and performance
(Marzullo et al. 2000). However, other components of the
cardiovascular system can be involved in the progression of
cardiomyopathy. Lie & Grossman (1980) documented the
presence of mitral and aortic abnormalities in 19% of their
autopsy series; ring fragility and leaflets disarray has also been
described (Ohtsuka et al., 1997), accompanied functionally
by regurgitation and stenosis. In such conditions, when the
functional complication requires therapeutic intervention,
replacement surgery seems to assure a better result than valve
plasty, thus improving long-term results (Ohtsuka et al., 1997).
Abnormalities of cardiac rhythm have also been docu-
mented, both with electrocardiography studies and Holter
recordings. The frequency of supraventricular premature
complexes in acromegaly is not significantly higher as
compared to the normal population (Surawicz & Mangiardi,
1977). Conversely, ectopic beats, paroxysmal atrial fibrillation,
paroxysmal supraventricular tachycardia, sick sinus syndrome,
ventricular tachycardia and bundle branch blocks are more
frequently recorded than in control subjects and are reported to
increase during physical exercise (Rodrigues et al., 1989;
Kahaly et al., 1992). Up to 41% of patients can suffer from
conduction disorders and recovery from acromegaly does not
significantly improve this rate (Rodrigues et al., 1989).
The haemodynamics of coronary perfusion have not been
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subjected to extensive study, but a prevalence of coronaro-
pathy of between 3 and 37% of cases has been reported in
different studies (reviewed by Harrison et al., 1978). Post-
mortem and heart-catheterization studies showed a prominent
involvement of small vessels, and thickening of intramural
vessels has been described in up to 22% of cases (Courville &
Mason, 1938; Hejtmancik et al., 1951; Lie & Grossman,
1980). Proximal arteries are generally normal, but they can be
either enlarged and tortuous or, rarely, stenotic (Lie &
Grossman, 1980). Finally, episodes of angina pectoris are
seldom reported, but the presence of chronic myocardial
ischaemia cannot be excluded.
From a functional perspective, the most striking cardiac
disorder of early acromegalic cardiomyopathy is inadequate
filling capacity. Doppler ultrasonography documented that
both the diastolic filling wave and the early to late mitral and
tricuspid velocity ratio are generally decreased (Sacca` et al.,
1994), whereas limited elasticity of myocardial fibres can
cause prolongation of the isovolumic relaxation time (Colao
et al. 2000a). This disorder can be asymptomatic for years
before clinical signs of cardiac involvement are experienced.
In the presence of diastolic impairment, the incomplete
recovery of an adequate preload can affect systolic parameters
during physical effort (Sicolo et al., 1993). In fact, the LV
ejection fraction and diastolic filling were found to be impaired
in 19% and 28% of 130 untreated acromegalic patients,
respectively (Colao et al. 2000a). In the advanced stage of
untreated disease, systolic disorders become more relevant
when the association with respiratory disorders, arterial
hypertension, metabolic diseases, arrhythmogenic phenomena
and coronaropathy can arise.
The application of equilibrium radionuclide angiography
seems to provide more accurate information on cardiac
performance not only in resting conditions but also at peak
exercise. Being operator independent, it allows measurement
of the ejection fraction from end-diastolic and end-systolic
counts; furthermore, filling and ejection rate can be normalized
to the end-diastolic heart rate (Bonow et al., 1981, 1985, 1988;
Cuocolo et al., 1995). Radionuclide studies have confirmed
that decreased diastolic filling capacities and impairment of the
ejection fraction after exercise can be recorded in 73% of
patients (Fazio et al., 1994). According to age stratification, in
a group of nonhypertensive patients we have observed a
decline in the ejection fraction response to physical exercise in
40% of those aged under 40 years and in 95% of older patients
(Colao et al., 1999a).
It should not be disregarded, however, that the coexistence
of other potential risk factors can play a negative role in the
progression of this sequence of events. Arterial hypertension
and metabolic complications have been already mentioned as
determinant factors in the setting of cardiovascular disorders in
acromegaly. In addition, cigarette smoking, and hereditary
disorders have been recognized as cardiovascular risk factors
in the normal population, whereas the occurrence of elevated
levels of lipoprotein-a, homocysteine, fibrinogen and trigly-
cerides have been associated with increased cardiovascular
morbidity (Harjai, 1999). A limited number of reports have
recently suggested that untreated acromegaly is associated
with elevated levels of triglycerides, apolipoprotein A-I and
apolipoprotein-E, fibrinogen, plasminogen activator inhibitor
activity and tissue plasminogen activator (Colao et al., 1997b;
Landin-Wilhelmsen et al., 1997; Wildbrett et al., 1997). Under-
standing their role in this multifactorial mosaic could help to
better define the individual progression of cardiovascular
complications in these patients.
Few data are currently available on vascular involvement in
acromegaly. A heterogeneous distribution of cardiac output
has recently been demonstrated in patients with active
acromegaly: the direct measurement of brachial artery
haemodynamics showed a lower regional blood flow and an
increased local resistance (Chanson et al., 1998). Morpholo-
gical alterations in the peripheral microcirculation have been
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Fig. 1 Left ventricular mass index (LVMi) measured by echocardio-
graphy in acromegalic patients aged (a) , 40 years or (b) between 40
and 60 years in comparison to sex- and age-matched control subjects.
Measurement of LVMi at baseline (A) was repeated in both groups
after 6 months (B), without any drug administration in controls and
after lanreotide (60–90 mg/month) or octreotide-LAR (20–30 mg/
month) in acromegalic patients. *P , 0·01 vs. controls; **P , 0·05
vs. baseline.
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also documented (Schiavon et al., 1999). We recently found a
significant increase of the carotid intima-media thickness
(IMT) in 30 active acromegalic patients (Colao et al. 2001) and
in 15 patients cured from acromegaly. Although such data
indicate that even long-term GH/IGF-I suppression was not
able to reverse intimal thickening, it should be noted that the
prevalence of well-defined atherosclerotic plaques was not
higher than in control subjects (Colao et al. 2001). On the other
hand, the prevalence of glucose tolerance alterations, hyper-
tension, unfavourable lipid profile and increased fibrinogen
levels was found to be slightly higher in the group of cured
acromegalic patients than in controls (Colao et al. 2001). The
adaptive increase of IMT has been suggested as a compensa-
tory response of the vessels to the changes in blood flow or
vascular tone (Bots et al., 1997). In fact, in our 75 subjects age
was one of the strongest predictors of IMT followed by GH
level (Colao et al. 2001). Furthermore, acromegalic patients
have an increase in insulin levels which are known to be
directly correlated with IMT (Kahn et al., 1993; Sowers et al.,
1993; Wu et al., 1994), that has been suggested to act as a risk
factor for myocardial infarction in adults (O’Leary et al.,
1999).
The effect of GH and IGF-I suppression on
acromegalic cardiomyopathy
A number of investigations (Table 1) have consistently
suggested that the progression of cardiac disorders can be
arrested by achieving therapeutic control of the disease.
Cardiovascular mortality in acromegaly mainly depends on
the estimated disease duration, patient’s age and the presence,
at diagnosis, of cardiovascular disease and arterial hyperten-
sion (Wright et al., 1970; Bates et al., 1993; Rajasoorya et al.,
1994). The last known GH value seems to better predict life-
threatening complications (Orme et al., 1998; Swearingen
et al., 1998). Mortality from cardiovascular accidents, in fact,
is significantly increased in the presence of uncontrolled
disease and long exposure to elevated hormone levels (Orme
et al., 1998). The suppression of GH concentration below 5–
7·5 mU/l (equal to 2·5 mg/l) and the inhibition of IGF-I-values
to the age-adjusted normal range reduce the cardiovascular
mortality to that of the general population rate (Orme et al.,
1998; Swearingen et al., 1998). Based on this viewpoint,
therapeutic success can consistently reduce both cardiovascu-
lar mortality and morbidity in acromegaly. Adenomectomy
has been reported to improve the mortality rate in patients
achieving either complete tumour removal or biochemical
control during medical therapy postsurgically (Swearingen
et al., 1998). The radio-therapeutic approach presents some
major limitations, including partial/delayed effectiveness and
high incidence of pituitary deficiency (Ferone et al. 2000).
Electrocardiographic and echocardiographic abnormalities
have been reported to worsen during long-term follow-up in
irradiated patients (Baldwin et al., 1985). Therefore, both
surgery and radiotherapy, when unsuccessful, cannot signifi-
cantly blunt the progression of cardiovascular complications.
In such circumstances, an adjunctive or substitutive medical
approach seems to exert a beneficial effect on cardiac mass and
structure. Due to their scant therapeutic effectiveness,
dopamine-agonists cannot adequately control the progression
of acromegaly, with few exceptions (Colao et al., 1997c; Abs
et al., 1998; Cozzi et al., 1998). Although there have been
reports of improvement of cardiac hypertrophy during long-
term treatment with bromocriptine (Luboshitzky & Barzilai,
1980), the lack of more extensive investigations limits any
conclusion. On the contrary, the extended use of somatostatin
analogues in the therapeutic management of acromegalic
patients has shown that suppression GH and IGF-I can be
obtained at least in 60% and 70% of cases, respectively
(Lamberts et al., 1996). Both short-lasting and long-lasting
formulations have been reported to successfully improve
cardiovascular indexes. Treatment with short-lasting s.c.
octreotide has been shown to reduce LV posterior wall and
interventricular septum thickness as early as 3 months
(Tokgo¨zoglu et al., 1994), and a more significant effect is
achieved with long-term treatment (Thuesen et al., 1989;
Pereira et al., 1991; Merola et al., 1993a). We reported a
significant reduction of indexed cardiac mass after 6 months of
therapy, and the prevalence of hypertrophy decreased from
72% to 27% (Merola et al., 1993a). Diastolic and systolic
improvement is more evident in patients obtaining GH
suppression and IGF-I normalization. A significant improve-
ment in LV ejection fraction was recorded in 13 patients
achieving biochemical control of the disease, out of 30 patients
subjected to a 1-year treatment with s.c. octreotide (Colao
et al., 1999b). A positive response to octreotide has been
reported also in acromegalic patients suffering from congestive
heart failure, who gained a significant improvement of
cardiac hypertrophy and an increase in cardiac output
(Chanson et al., 1989, 1990). Similarly, cardiopulmonary
performance, impaired in acromegalic patients when compared
to controls, was acutely improved by continuous infusion of s.c.
octreotide for 24 h (Giustina et al., 1995). Depot formulations
of somatostatin analogues, namely slow-release lanreotide and
long-acting release octreotide (octreotide-LAR), allow more
effective and sustained biochemical control of the disease,
improving patients’ compliance (Caron et al., 1997; Gillis
et al., 1997; Colao & Lombardi, 1998; Lancranjan & Atkinson,
1999). Lanreotide has been shown to induce a significant and
progressive reduction in LVMi and isovolumic relaxation
time after 3, 6 and 12 months of therapy (Baldelli et al., 1999),
allowing a consistent improvement of diastolic filling
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capacities. This observation has been confirmed in another
study, where a correlation between the reduction of the cardiac
mass and the suppression of GH levels was suggested (Hradec
et al., 1999). Preliminary data on three patients treated for
18 months with octreotide-LAR has similarly shown a sig-
nificant reduction in cardiac mass (Colao et al., 1997a). These
data were confirmed in another series of previously untreated
acromegalic patients after 6 months of octreotide-LAR treat-
ment (Colao et al. 2000b). In particular, a significant decrease in
the left ventricular mass ranging 5·2–35·2% was observed in all
patients (Fig. 2), while an increase in the response of the LV
ejection fraction at peak exercise was found only in patients
achieving disease control (Fig. 2). Despite these results, it is still
debatable whether the cardiac benefit achieved after effective
therapy for acromegaly could restore the heart features to a
predisease condition. The overall reduction of cardiac mass after
treatment appears to be close to 20% of basal values, and the
incidence of complete normalization of cardiac structure and
performance difficult to assess, due to the short duration of
follow-ups so far reported. Interestingly, young patients with
short disease duration showed average LVMi values comparable
to age-matched controls 6 months after treatment either with
lanreotide and octreotide-LAR (Fig. 1), and 50% of the entire
patient group with cardiac hypertrophy regained a normal LVMi
(unpublished data).
It is thus conceivable that more extensive data will shed new
light on this question when prolonged follow-up results will be
reported.
Cardiovascular involvement in GH deficiency
Whereas the cardiac involvement in acromegaly had already
been described at the end of the 19th century (Huchard, 1895),
the evidence that GH deficiency (GHD) can cause cardiovas-
cular impairment has only recently been described. Beyond
their growth and differentiation effect on whole body organs
and tissues as their metabolic role in glucose uptake, glycogen
synthesis and amino-acid transport, GH and IGF-I were also
demonstrated to display relevant effects on cardiac develop-
ment and performance. Long-standing GHD in adult subjects is
associated with changes in bone turnover and body composi-
tion, impairment in lipid profile, reduction in exercise capacity
and abnormalities in cardiac function (De Boer et al., 1995;
Carrol & Christ, 1998; Vance & Mauras, 1999). The attention
of several investigators has focussed on this life-threatening
complication. In fact, epidemiological data suggest that adults
with hypopituitarism have reduced life expectancy compared
with healthy controls, with a greater than twofold increase
mortality for cardiovascular disease (Rose´n & Bengtsson,
1990). These epidemiological findings were confirmed in
Table 1 Overview of the effect of different treatments on cardiac parameters in patients with acromegaly
Author
Total
patients Treatment Follow-up Methods Results
Baldwin et al., 1985
Hayward et al., 1987
11
10
RT
Surgery 1 RT
3–17 years
1–11 years
ECG,ECHO
X-ray, ECG
Increased prevalence of cardiovascular events.
Two of six cured improved, three not cured died.
Thuesen et al., 1989 9 Octreotide 12 months ECHO Decreased blood pressure and LV mass.
Pereira et al., 1991
Lim et al., 1992
Merola et al. 1993a
5
16
11
Octreotide
Octreotide
Octreotide
6 months
2 months
6 months
ECHO
ECHO
ECG, ECHO
Significantly decreased IVST, improved diastolic filling.
Rapid decrease of the LV mass in patients with hypertrophy
but not in those without hypertrophy.
Significantly decreased LVM, improved diastolic filling,
unchanged blood pressure and ejection fraction.
Tokgo¨zoglu et al., 1994 6 Octreotide 6 months ECG, ECHO Significantly decreased LVM, increased time in treadmill
exercise, uchanged blood pressure and ejection fraction.
Colao et al., 1999 30 Octreotide 12 months ERA Significantly decreased heart rate, and increased ejection
fraction in controlled patients, significantly increased blood
pressure and decreased ejection fraction in noncontrolled
patients.
Baldelli et al., 1999 13 Lanreotide 12 months ECHO Significantly decreased LVM, improved diastolic filling,
unchanged blood pressure and ejection fraction.
Hradec et al., 1999
Colao et al. 2000c
13
15
Lanreotide
Octreotide-LAR
12 months
6 months
ECHO
ECHO, ERA
Significantly decreased LVM, unchanged blood pressure,
diastolic filling, and ejection fraction.
Significantly decreased LVM in all patients, significantly
increased ejection fraction at rest and at peak exercise in
controlled patients but not in noncontrolled patients.
RT, radiotherapy; ECG, elecrocardiogram; ECHO, echocardiogram; ERA, equilibrium radionuclide angiography; X-ray, radiography; LV, left
ventricle; IVST, interventricular septum thickness; LVM, left ventricular mass.
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another study demonstrating a standardized mortality ratio of
1·74 for cardiovascular disease among 344 patients with
hypopituitarism (Bulo¨w et al., 1997; Erfurth & Hagmar, 1998).
All these reports suggested that the factor responsible for the
increased mortality was the GHD. A direct effect of GH
deficiency on the heart is highly reliable, although the
possibility that gonadal steroid under-replacement and gluco-
corticoid over-replacement can also negatively affect the
cardiovascular system cannot be ruled out. Overall, the
negative effect of GHD on cardiovascular functions seems to
be due not only to a direct effect played by GH and IGF-I (see
experimental basis) but also to an indirect mechanism exerted
by unfavourable lipid profile, hypercoagulability and athero-
sclerosis, as well as decreased muscle performance, pulmonary
capacity and endothelial function (reviewed by Beshyah &
Johnston, 1999).
A decrease in cardiac size following hypophysectomy,
which was reversed by GH administration, was first demon-
strated in experimental models (Beznak, 1954; Hjalmarson
et al., 1969), whereas abnormalities in cardiac structure and
function in humans have only recently been demonstrated.
Using Doppler ultrasonography, a decrease in the thickness of
the LV posterior wall and of the interventricular septum,
together with a decrease in the LV internal diameter, was
reported in childhood-onset GHD patients (Amato et al., 1993;
Merola et al., 1993b). In particular, a decrease in the thickness
of the LV posterior wall and the interventricular septum was,
respectively, found in 22% and 33% of adult patients with
childhood-onset GHD with an average decrease in cardiac size
of 36% (Merola et al., 1993b). A significant decrease of 14%
of the LV ejection fraction was also observed (Merola et al.,
1993b). In one study, GHD patients were reported to have a
decrease in LV posterior wall and interventricular septum
thickness, although no difference of the LVMi, LV internal
diameter and systolic function evaluated as LV ejection
fraction between patients and controls was noted (Beshyah
et al., 1995). Contrastingly, other studies on adult patients both
with childhood-and adulthood-onset GHD, have shown no
difference in the morphological and functional parameters of
the LV between patients and controls (Thuesen et al., 1994;
Beshyah et al., 1995; Dunne et al., 1995; Valcavi et al., 1995).
Normal values of LV geometry were also found in GHD
patients by Nass et al. (1995), although no control subjects
were studied. Serum IGF-I levels were found to be correlated
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with the LVM and the total fat-free mass in hypopituitary
subjects (Beshyah et al., 1995; Shahi et al., 1992), suggesting
that GH can affect cardiac size and body composition to the
same extent. Although both patients with childhood-onset and
adulthood-onset GHD show decreased vitality, energy, and
physical mobility together with several psychological symp-
toms, the former were shown to present more severe symptoms
than the latter (Attanasio et al., 1997). No report has compared
cardiac characteristics in patients with childhood-onset and
adulthood-onset disease so far except for one study, where
cardiac performance was evaluated by equilibrium radio-
nuclide angiography in a group of patients younger than
40 years of age. Although no data on cardiac geometry were
available, decreased LV ejection fraction at rest (of 17%) and
at peak exercise (of 29%) as compared to sex- and age-
matched controls was found in both childhood-and adulthood-
onset GHD patients without any difference between them
(Longobardi et al., 1998).
To further evaluate the influence of GHD during adult age,
cardiac performance was investigated in a large cohort divided
in young patients aged , 40 years, and middle-aged patients
aged between 41 and 60 years. Diastolic filling abnormalities
and impaired response of LV ejection fraction at peak exercise
were found in as many as 65·4% of patients with GHD
acquired in adulthood, regardless the age of onset of the
disease (Colao et al., 2000c). The impairment of LV
performance can be due either to a cardiac muscle disease
directly caused by the deficiency of GH and IGF-I themselves
or to altered haemodynamic conditions, low heart rate and
blood pressure indirectly caused by GH and IGF-I deficiency,
or both. A characteristic hypokinetic syndrome of GHD was,
however, only found in young patients, indicating that the age
of onset play a relevant role in determining the severity of
cardiac impairment in GHD patients (Colao et al., 2000c). As
in the young patients, elderly patients with GHD also seem to
present a specific clinical and biochemical syndrome (Toogood
et al., 1996a, 1996b). In fact, bone mineral density was
reported either to be normal (Toogood et al., 1997) or reduced
(Colao et al., 1998b), whereas body composition was
consistently reported to be altered in these patients (Toogood
et al., 1996b; Colao et al., 1998b). Scant data are available on
cardiac size and performance in elderly GHD patients. We
have recently reported in 11 GHD patients aged over 60 years
that cardiac mass was similar to that observed in age- and sex-
matched controls (LVMi 97·6 ^ 1·8 vs. 99·9 ^ 1·5 g/m2)
while the LV ejection fraction at peak exercise was markedly
depressed in patients compared to controls (51 ^ 2·5% vs.
73·3 ^ 3%, P , 0·001) (Colao et al., 1999c). A normal
response of LV ejection fraction at peak exercise was found in
eight controls (72·7%) and in two out of 11 patients (18·2%)
(Colao et al., 1999c), giving a result that was similar to that
observed in younger patients (Cittadini et al., 1994; Cuocolo
et al., 1996; Longobardi et al., 1998; Colao et al. 2000c).
Another point that should not be disregarded is the presence
of endothelial dysfunction in GHD. Circulating IGF-I levels
seem to play a role on endothelial properties. Endothelial cells
possess high-affinity binding sites for IGF-I (Delafontaine
et al., 1991) and IGF-I was demonstrated to increase nitric
oxide (NO) production in in vitro experimental procedures
(Walsh et al., 1996), so contributing to the regulation of
vascular tone (Guler et al., 1989; Hirshberg et al., 1993;
Copeland & Sreekuran, 1994; Tsukahara et al., 1994; Bo¨ger
et al., 1996). It should be considered that a decreased NO
activity is associated with impaired arterial vasodilator
capacity, increased platelet aggregability and intimal thicken-
ing (Bo¨ger et al., 1996). An inverse relationship between free
IGF-I levels and intima-media thickness (IMT) has been
recently reported in healthy elderly subjects (Janssen et al.,
1998). Moreover, IGF-I may potentially be an important
regulator of regional blood flow: IGF-I was demonstrated to
possess a direct impact on the vasculature and to attenuate
contractility in rat arteries, an effect related to NO production
itself (Gryglewski et al., 1986). Finally, the infusion of
recombinant human IGF-I increases renal blood flow and
decreases local vascular resistance both in humans and rats
(Guler et al., 1989; Hirshberg et al., 1993). As IGF-I is not
only secreted by vascular smooth muscle cells but also
stimulates vascular NO production, it has been suggested that
this hormone might play a significant paracrine/autocrine role
in the regulation of local blood flow (Delafontaine et al.,
1991). It is therefore likely that patients affected with GHD
might diplay both a specific disarray of cardiomyocytes,
leading to impairment of cardiac performance, and an
alteration at the vascular level. Less distensibility of aorta
(Lehmann et al., 1993) and endothelial dysfunction (Evans
et al., 1999) together with a significant increase in IMT at the
level of both common carotid arteries (Markussis et al., 1992;
Capaldo et al., 1997; Borson-Chazot et al., 1999; Pfeifer et al.,
1999) were demonstrated in patients with GHD developing
either during childhood or adulthood. These patients also had
intense sympathetic nerve activity, likely of central origin,
which may be another important mechanism of increased
cardiovascular mortality (Sverrisdottir et al., 1998).
On this basis, a careful cardiological and vascular assess-
ment of adult patients with GHD could be helpful both in
diagnostic strategies and in therapeutic monitoring of the early
stages of cardiac failure and atherosclerosis.
The effect of GH replacement therapy on cardiac size
and performance
Although the administration of GH to GHD adults reverses
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many of the changes in body composition, bone mineral
density, exercise capacity and strength, and improves the lipid
profile (reviewed by Carrol & Christ, 1998; Beshyah &
Johnston, 1999; Vance & Mauras, 1999), little is known about
the ultimate efficacy of GH treatment in reversing the
cardiovascular risk. The analysis of the results is further
complicated by the fact that the doses of GH employed have
gradually been reduced during the last decade and have ranged
from 6 to 26 mg/kg body weight in different studies. GH was
reported to increase cardiac mass in some short-term studies
(Amato et al., 1993; Caidahl et al., 1994; Valcavi et al., 1995;
Johansson et al., 1996) but not in others (Beshyah et al., 1995;
Thuesen et al., 1994; Nass et al., 1995). In one study (Amato
et al., 1993), a 26% increase of the LVMi and a 12% increase
in the LV ejection fraction followed GH replacement
treatment: these effects disappeared after 6 months of GH
discontinuation. An increase in cardiac mass was found either
with higher (Johansson et al., 1996) or lower GH replacement
dosages (Valcavi et al., 1995). Interestingly, a significant
increase in cardiac mass was reported by Ter Maaten et al.
(1999) during the first year of GH replacement at supraphy-
siological doses. However, the hypertrophic effect of GH
replacement subsided during treatment and was not detecta-
ble 2 years after therapy continuation; cardiac mass was
similar to pretreatment values after 10-years’ replacement
(Ter Maaten et al., 1999). No difference in cardiac size
between baseline and GH treatment data was reported also by
Gibney et al. (1999) in another 10-year follow-up study. No
change in cardiac function by echocardiography was reported
by Nass et al. (1995) while improvement both in the diastolic
filling and systolic function was observed by radionuclide
angiography after 6 months of GH replacement in small series
of childhood-onset GHD adults (Cittadini et al., 1994; Cuocolo
et al., 1996). Similarly, a significant increase in stroke volume
was observed during the first year of GH therapy in men with
childhood-onset GHD (Ter Maaten et al., 1999). The increase
in stroke volume was attributed to fluid retention on the basis
of an increased preload, as indicated by the concomitant rise in
LV end-diastolic volume (Ter Maaten et al., 1999). However, a
direct cardiac inotropic effect of GH can not be ruled out
(Valcavi et al., 1995). During the 10-year follow-up Ter
Maaten et al. (1999) also reported a noteable increase in the
cardiac index together with an increase in heart rate over time.
The improved cardiac performance was also sustained by a
remarkable increase in exercise performance. In a recent
review of a cohort of young GHD patients, we observed a
significant increase of the LV ejection fraction at peak exercise
during a 12 month GH replacement course (unpublished data,
Fig. 3). However, the exercise-induced changes of LV ejection
fraction remained significantly lower than controls after
treatment (Fig. 3). In 20 GHD adults aged below 40 years,
no difference both of LV ejection fraction and diastolic filling
was found between childhood-onset and adulthood-onset
patients (unpublished data, Fig. 3). In line with previous reports
(reviewed by Carrol & Christ, 1998; Beshyah & Johnston, 1999;
Vance & Mauras, 1999), we found a remarkable increase
both in exercise capacity (from 84·2 ^ 3·4 to 98·7 ^ 4 watts,
P  0·002; controls 100·0 ^ 4·1 watts) and duration (from
7·3 ^ 0·4 to 8·9 ^ 0·4 minutes, P  0·0003; controls, 9·6 ^
0·2 minutes).
A beneficial effect of GH replacement on the vascular
abnormalities of GHD has also recently been demonstrated.
GH treatment in hypopituitary GHD men reversed early
morphological and functional atherosclerotic changes in major
arteries (Pfeifer et al., 1999). The reduction in IMT observed in
GH treated GHD patients occurred without a consensual
improvement of cardiovascular risk factor parameters, as only
a transient 10% decrease in LDL-cholesterol levels was found
after 6 months (Borson-Chazot et al., 1999). These findings
suggested a direct effect of GH on the arterial wall (Bots et al.,
1997). In fact, blood flow responses to acetylcholine and
nitroprusside were significantly greater after GH replacement
(Christ et al., 1999).
However, no data are available on the effect of GH
replacement on cardiovascular-related morbidity and mortality.
Perspectives in the treatment of heart failure with GH
The rationale for exploring GH as a therapeutic agent in
idiopathic dilated cardiomyopathy relies on a large body of
experimental data. GH and/or IGF-I showed beneficial effects
in experimental models of heart failure (Duerr et al., 1995;
Yang et al., 1995; Duerr et al., 1996). In rats with experimental
heart failure due to coronary artery ligation, myocyte growth
was obtained in the residual healthy myocardium and was
associated with a significant functional improvement after
treatment with IGF-I (Duerr et al., 1995). Moreover, in rats
with LV failure, GH and IGF-I administration 1 month after
experimental myocardial infarction was associated with
increased cardiac output and decreased systemic vascular
resistance (Duerr et al., 1996). Improvement of cardiac
function in rats with experimental heart failure was shown
after administering GH alone (Yang et al., 1995), and after
pretreatment with angiotensin-converting enzyme inhibitors
(Jin et al., 1995). In a few patients with GHD and heart failure
due to dilated cardiomyopathy, a prompt recovery of cardiac
performance was described after GH replacement had been
started (Cuneo et al., 1989; Frustaci et al., 1992; Fazio et al.,
1996a). Based on this evidence, GH was suggested in the
treatment of idiopathic dilated cardiomyopathy, a condition in
which compensatory cardiac hypertrophy is believed to be
deficient. A pilot study performed in a small series of patients
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with idiopathic dilated cardiomyopathy and heart failure
demonstrated that the administration of GH for 3 months
induced myocardial growth, improved contractility, reduced
myocardial oxygen consumption and, finally, improved
exercise tolerance (Fazio et al., 1996b). In another study,
however, GH or placebo was injected subcutaneously for
3 months and no significant changes in body weight, walking
test, haemodynamic parameters or in the New York Heart
Association class were found (Osterziel et al., 1998). However,
GH treated patients had an increase in ventricular mass
(Osterziel et al., 1998). Volterrani et al. (1997) also
demonstrated beneficial effects in patients with chronic heart
failure due to either ischaemic or idiopathic dilated cardio-
myopathy, with improvement in haemodynamics when GH
was added as a short-term infusion. On the other hand,
alterations in the GH/IGF-I axis have been reported in patients
with idiopathic dilated cardiomyopathy, as low IGF-I levels
(Broglio et al., 1999), subnormal spontaneous GH secretion
(Giustina et al., 1996), and low responsiveness of GH after
GHRH alone or combined with arginine (Broglio et al. 2000)
have been reported in these patients. Despite the low IGF-I
levels, the sensitivity to exogenous GH administration was
reported to be normal (Broglio et al., 1999), thus potentially
adding another endocrine rationale to the GH treatment in
these patients. However, GH treatment in these patients was
accompanied by side-effects either related to the increase in
circulating IGF-I levels to supra-physiologic levels (Turner &
Wass, 1996) and to the risk of dysrhythmia (Frustaci et al.,
1996). Furthermore, in a placebo-controlled 3-month study,
GH treatment of patients with chronic heart failure of various
aetiologies did not significantly improve their cardiac function,
although it was safe and well tolerated without serious adverse
effects (Isgaard et al., 1998). However, a dose-dependent
increase in IGF-I and IGFBP3 levels was observed during GH
treatment in 20 clinically stable patients with moderate heart
failure, and the increase in IGF-I induced by 10 mg/kg/day of
GH correlated positively with the LV ejection fraction and
inversely with the LV end-diastolic and end-systolic dimen-
sions (Osterziel et al., 2000). This finding suggested that
individual dose adjustments are a basic requisite for the
success of GH therapy in heart failure. An overview of the
effects of GH treatment in heart failure is shown in Table 2.
75
50
25
0
LV
E
F 
at
 r
es
t 
(%
)
(a)
400
300
200
100
0
se
ru
m
 IG
F-
I l
ev
el
s 
(m
g
/l) (b)
75
50
25
0
LV
E
F 
at
 p
ea
k 
ex
er
ci
se
 (
%
) (c)
3
2
1
0
P
FR
 (
E
D
V
/s
ec
)
(d)
30
20
10
0
–10
–20
D
 L
V
E
F 
(%
)
(e)
4
3
2
1
0
P
E
R
 (
E
D
V
/s
ec
)
(f)
**
**
**
*
***
Fig. 3 Effect of GH replacement treatment
for 12 months in 20 patients with GH
deficiency and age below 40 years (before: B
and after: p GH treatment) as compared to
sex- and age-matched control subjects (A).
From top to bottom are shown the left
ventricular ejection fraction at rest (a), at peak
exercise (c), and the exercise-induced changes
of ejection fraction (e), IGF-I levels (b), the
peak filling rate (PFR; d) and the peak
ejection rate (PER; f). Cardiac parameters
were assessed by radionuclide angiography.
*P , 0·001; **P , 0·0001; ***P  0·001
†P  0·02; ††P  0·0001; †††P  0·03;
‡P  0·0005; ‡‡P  0·004.
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GH secretagogues (GHSs) and the heart
The pathophysiology of the GH/IGF-I axis, and more
generally, of pituitary secretion has been recently re-evaluated
after the introduction of GHSs (Casanueva & Dieguez, 1999).
GHS are synthetic compounds developed to release GH in
vitro, acting though specific receptors different from those of
GHRH (Bowers et al., 1991). GHSs mimic an endogenous
factor activating the GHS receptor at the pituitary and
hypothalamus (Casanueva & Dieguez, 1999). The GHS
receptor was recently cloned (Howard, 1996), so demonstrat-
ing that GHS is a new physiological system regulating GH
secretion together with GHRH and somatostatin (Casanueva &
Dieguez, 1999). Beyond the effects on GH secretion, GHSs
seem to display specific actions on the heart. In particular,
hexarelin (HEX), an hexapeptide GHS, possesses specific
receptors on cardiomyocytes at partial variance with other
GHSs (Bodart et al., 1999). Protective actions of HEX on the
heart were demonstrated in a model of aged rats with induced
postischaemic ventricular dysfunction (Rossoni et al., 1998).
Similarly, beneficial effects of HEX on cardiac performance
were reported in rats after experimental myocardial infarction
(Tivesten et al. 2000) and in perfused hearts from GHD rats
(De Gennaro Colonna et al., 1997). In another study, HEX
treatment for 7 days at the dose of 80 mg/kg s.c. prevented the
exacerbation of the ischaemia-reperfusion damage induced by
hypophysectomy in the rat (Locatelli et al., 1999). In this
model HEX prevented increases in LV end-diastolic pressure,
coronary perfusion pressure, reactivity of the coronary
vasculature to angiotensin II and release of creatinine kinase
in the heart perfusate (Locatelli et al., 1999).
A single i.v. injection of HEX was recently demonstrated to
increase the LV ejection fraction, without any change in mean
blood pressure or heart rate in healthy men (Bisi et al., 1999b).
No such result was obtained with a single GH administration
(Bisi et al., 1999b). In addition, HEX increased LV ejection
fraction in patients with GHD (Bisi et al., 1999c). Whether the
cardiac actions of HEX directly involve the activation of
specific receptors or occur indirectly through stimulation of the
GH/IGF-I axis remains unknown.
Conclusions
From the first observations of Huchard in 1895, describing
cardiovascular abnormalities in acromegaly, to the evidence of
premature mortality from cardiovascular disease in hypopitui-
tarism (Rose´n & Bengtsson, 1990; Bates et al., 1996; Bu¨low
et al., 1997), great efforts have been made to understand the
pathophysiology of the GH/IGF-I axis in cardiac development
and function. Theoretically, the impairment in cardiac per-
formance could be due to a large number of factors, including a
direct reduced pump function, increased vascular resistance
and reduction of pulmonary function and/or muscle strength.
Generally, patients with GH excess and deficiency have
varying degree of cardiovascular impairment at different
levels. In the management of patients with acromegaly and
GHD, careful evaluation of cardiac function at diagnosis and
during follow-up seems, thus, to be mandatory. However, it
should be pointed out that no data are available on the
reversibility of cardiovascular mortality after GH replacement
in GHD patients, and the actual role of GH levels on the
cardiovascular mortality in nonhypopituitary patients is still
questioned (Maison et al., 1998). Conversely, additional end-
points such as mortality, morbidity and survival time until
successful cardiac transplantation as well as performance after
transplantation would be required in long-term studies, in order
to define the role, the mechanism of action and the clinical
applicability of GH in heart failure.
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